Tirofiban with aspirin tested in moderate ischemic stroke
Tests tirofiban plus aspirin against placebo plus aspirin in adults with moderate ischemic stroke.
Plain-language title generated from the registry record
Registry title: Tirofiban Combined With Aspirin in Moderate Ischemic Stroke
Key facts
- Where
- Haikou, Jingdezhen, Jiujiang, and Nanchang, ChinaSee the 5 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 80 with an acute moderate ischemic stroke, who are treated within 24 hours of last known well. They get aspirin plus either tirofiban or a placebo.
- Age
- 18 to 80 years
- Sex
- All sexes can join.
- Disease stage
- Acute ischemic stroke, NIHSS score 4-10, with at least one of item 5 (upper limb) or item 6 (lower limb) ≥ 1. Randomization within 24 hours of last known well.
- Earlier treatment
- Cannot have received, or be planned to receive, thrombolysis or endovascular treatment. Cannot have planned use of NSAIDs that affect platelet function.
Main reasons for not taking part
- Bleeding in the brain on CT or MRI, or a past brain bleed
- Reperfusion therapy (thrombolysis or endovascular treatment) given or planned
- A definite heart source of clots, or a clear need for blood thinners (anticoagulation)
- Severe systemic disease such as severe infection or severe liver or kidney problems
- Allergy to tirofiban or aspirin
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07760922, who can take part
Where in China
- The First Affiliated Hospital of Hainan Medical UniversityHaikou, ChinaNo longer taking part
- The First People's Hospital of Jingdezhen CityJingdezhen, ChinaNo longer taking part
- The First People's Hospital of Jiujiang CityJiujiang, ChinaNo longer taking part
- The First Affiliated Hospital of Gannan Medical UniversityNanchang, ChinaNo longer taking part
- The First Affiliated Hospital of NanChang UniversityNanchang, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xinqiao Hospital of Chongqing
- Trial code
- NCT07760922
- Record updated
- 12 August 2026
- Original description
Ischemic stroke accounts for the majority of stroke cases in China, and moderate ischemic stroke (NIHSS 4-10) carries a high risk of early neurologic deterioration (END) and long-term disability. Although intensified antiplatelet strategies reduce END, they have not consistently improved long-term functional outcome. Tirofiban, a selective glycoprotein IIb/IIIa receptor inhibitor, has shown a clinically meaningful trend toward better 90-day functional outcome (mRS 0-1) in prior tirofiban trials, but existing sample sizes were underpowered to detect this difference.Read full original descriptionShow less
Efficacy and Safety of Tirofiban Combined With Aspirin in Moderate Ischemic Stroke: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Ischemic stroke accounts for the majority of stroke cases in China, and moderate ischemic stroke (NIHSS 4-10) carries a high risk of early neurologic deterioration (END) and long-term disability. Although intensified antiplatelet strategies reduce END, they have not consistently improved long-term functional outcome. Tirofiban, a selective glycoprotein IIb/IIIa receptor inhibitor, has shown a clinically meaningful trend toward better 90-day functional outcome (mRS 0-1) in prior tirofiban trials, but existing sample sizes were underpowered to detect this difference.
TAMIS is a multicenter, randomized, double-blind, placebo-controlled superiority trial in patients with acute moderate ischemic stroke (NIHSS 4-10) within 24 hours of last known well. Eligible patients are randomized 1:1 to tirofiban plus aspirin versus placebo plus aspirin, both on a background of guideline-based standard medical care. The primary efficacy endpoint is the proportion of patients with an excellent functional outcome (mRS 0-1) at 90 days. The primary safety endpoint is symptomatic intracranial hemorrhage within 48 (±12) hours by the Heidelberg criteria.
Inclusion: Age 18-80 years; Acute ischemic stroke; time from last known well to randomization ≤ 24 hours; Pre-randomization NIHSS score 4-10, with at least one of item 5 (upper limb) or item 6 (lower limb) ≥ 1; Pre-stroke modified Rankin Scale (mRS) ≤ 1; Written informed consent provided by the patient or a legally authorized representative.
Exclusion: Has received or is planned to receive reperfusion therapy (thrombolysis or endovascular treatment); Planned or likely revascularization (any angioplasty or vascular surgery) within the next 3 months; Planned surgery or intervention requiring discontinuation of antiplatelet therapy; Prior non-atherosclerotic arterial disease, including moyamoya disease, arterial dissection, fibromuscular dysplasia; Prior neurologic or psychiatric disease that would interfere with neurologic assessment; Intracranial hemorrhage confirmed by CT or MRI; Definite indication for anticoagulation (atrial fibrillation, mechanical heart valve, deep vein thrombosis, pulmonary embolism); Severe systemic disease (e.g., severe infection, severe hepatic or renal dysfunction); Allergy to tirofiban and/or aspirin; History of intracranial hemorrhage; Gastrointestinal bleeding or major surgery within the past 3 months; Stroke caused by angiography or surgery; Other structural brain disease (vascular malformation, tumor, abscess, multiple sclerosis, etc.) confirmed by CT/MRI; Advanced disease with expected survival < 6 months; Any definite cardioembolic source: chronic/paroxysmal atrial fibrillation, sick sinus syndrome, mitral stenosis, mechanical heart valve, endocarditis, intracardiac thrombus or vegetation, myocardial infarction within 3 months, dilated cardiomyopathy, left atrial spontaneous echo contrast, ejection fraction < 30%; Planned use of NSAIDs affecting platelet function; Pregnancy or lactation; Participation in another clinical trial; Expected inability to complete follow-up.